Stock Market Reviews

Read and share opinions on SION (Sionna Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors
  Nov 14, 2025
• Sionna Therapeutics (SION): Assessing Valuation After a Rapid 95% 3-Month Share Price Surge
  Nov 7, 2025
• Sionna Therapeutics Reports Third Quarter 2025 Financial Results
  Nov 5, 2025
• Sionna Therapeutics to Participate in Upcoming November Investor Conferences
  Nov 4, 2025
• Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors
  Oct 31, 2025
• Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
  Oct 24, 2025
• Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
  Oct 21, 2025
• Sionna Therapeutics (SION): Assessing Valuation After Recent Share Price Surge
  Oct 13, 2025
• Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
  Oct 1, 2025
• All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy
  Sep 15, 2025
• Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?
  Sep 9, 2025
• Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
  Sep 8, 2025
• Sionna Therapeutics to Participate in Upcoming September Investor Conferences
  Aug 27, 2025
• Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
  Aug 25, 2025
• Sionna Therapeutics Reports Second Quarter 2025 Financial Results
  Aug 11, 2025
• Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
  Jun 6, 2025
• Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
  Jun 4, 2025
• Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
  Jun 4, 2025
• Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
  Jun 3, 2025